Trexquant Investment LP Sells 46,964 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Trexquant Investment LP lessened its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 47.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,585 shares of the biopharmaceutical company’s stock after selling 46,964 shares during the quarter. Trexquant Investment LP’s holdings in Intra-Cellular Therapies were worth $4,392,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Norges Bank bought a new stake in Intra-Cellular Therapies during the fourth quarter worth $268,347,000. Raymond James Financial Inc. bought a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at about $76,451,000. TimesSquare Capital Management LLC lifted its stake in Intra-Cellular Therapies by 91.8% in the 4th quarter. TimesSquare Capital Management LLC now owns 840,269 shares of the biopharmaceutical company’s stock valued at $70,179,000 after purchasing an additional 402,186 shares during the last quarter. Franklin Resources Inc. lifted its stake in Intra-Cellular Therapies by 9.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock valued at $129,463,000 after purchasing an additional 155,655 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in Intra-Cellular Therapies by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock worth $811,928,000 after purchasing an additional 93,107 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ ITCI opened at $131.87 on Friday. The stock has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a fifty-two week low of $64.09 and a fifty-two week high of $131.98. The business has a fifty day moving average price of $129.62 and a two-hundred day moving average price of $101.61.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analyst Upgrades and Downgrades

ITCI has been the subject of a number of recent analyst reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Leerink Partnrs cut shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research report on Saturday. They issued a “hold” rating on the stock. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Eleven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $106.23.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.